Pricing Log in Create free account

Oculis Holding AG (OCS) vs Relmada Therapeutics, Inc. (RLMD)

Oculis Holding AG and Relmada Therapeutics, Inc. are both Biotechnology companies. Oculis Holding AG and Relmada Therapeutics, Inc. are of similar size ($421.6M and $402.1M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −8,709.4%) and the higher return on invested capital (0.00% vs −12,858.7%). Across the 14 metrics below, Relmada Therapeutics, Inc. leads on 8 and Oculis Holding AG on 6.

Valuation

Metric OCS RLMD Biotechnology median
P/E n/m n/m 10.60
P/S 393.17 n/m 9.40
P/B 1.80 2.12 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 175.67 n/m 9.02
Earnings yield (23.24%) (24.49%) (32.88%)
Free cash flow yield (18.69%) (29.06%) (23.13%)

Profitability

Metric OCS RLMD Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (9,551.41%) 0.00% 0.00%
Net margin (8,709.42%) 0.00% 0.00%
Free cash flow margin (7,237.57%) 0.00% 0.00%
Return on equity (48.81%) (55.66%) (51.96%)
Return on assets (41.38%) (51.57%) (46.06%)
Return on invested capital (12,858.67%) 0.00% 0.00%

Growth

Metric OCS RLMD Biotechnology median
Revenue growth (TTM) 25.01% — 6.76%
EPS growth (last fiscal year) 5.39% 45.28% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric OCS RLMD Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 10.41 29.52 4.97
Net debt to EBITDA 2.60 1.57 1.01

Dividend

Metric OCS RLMD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric OCS RLMD Biotechnology median
Market cap 421.63m 402.14m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack